ReviewFrontiers in pharmacology2026

Targeting NAT10 with Remodelin in cancer drug resistance: mechanisms, preclinical evidence, and combination strategies.

Feifeng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.